Zydus Lifesciences Ltd and CSIR-Central Drug Research Institute (CDRI) have joined forces to develop an innovative drug targeting osteoporosis induced by chronic kidney disease (CKD). Chronic kidney disease, affecting over 10% of the global population, has long posed severe health challenges, leading to complications such as bone mineral disruptions and an increased risk of fractures. […]
Novo Nordisk, a global leader in pharmaceuticals, has announced a major setback as its CLARION-CKD phase 3 trial failed to meet its primary endpoint, prompting the company to recognize an impairment loss of approximately DKK 5.7 billion. The trial, which was a pivotal part of Novo Nordisk’s efforts in addressing uncontrolled hypertension and advanced chronic […]
In a significant development for the treatment of anemia related to chronic kidney disease (CKD) in dialysis patients, Akebia Therapeutics, Inc. (Nasdaq: AKBA), a pioneering biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of Vafseo (vadadustat) Tablets. This approval marks a crucial milestone in providing an alternative and innovative treatment option for […]
In a significant development for the Indian healthcare sector, Sun Pharmaceutical Industries Limited and Bayer have announced a collaborative agreement to market and distribute a second brand of Finerenone in India. This move is set to revolutionize the treatment landscape for chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM). Finerenone: A Game-Changer […]
Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective aldosterone synthase inhibitor. The data highlights a substantial up to 39.5% reduction in albuminuria when BI 690517 is used in conjunction with empagliflozin, an established SGLT2 inhibitor, compared to a placebo. This study represents the first of […]
Recent findings from the ZENITH-CKD Phase IIb trial, conducted by AstraZeneca, have demonstrated a significant decrease in albuminuria among CKD patients treated with a combination of Zibotentan and Dapagliflozin. The trial has brought to light a notable decrease in the urinary albumin-to-creatinine ratio (UACR) in participants, offering a new avenue for CKD treatment. Significant UACR […]
Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited have announced a licensing agreement for the co-marketing of Desidustat, an innovative oral anemia treatment for Chronic Kidney Disease (CKD) patients in India. This partnership signifies a significant advancement in CKD anemia treatment, offering a more convenient oral pill form as opposed to traditional injectable therapies. Licensing […]
The U.S. Food and Drug Administration (FDA) has granted approval for Jardiance (empagliflozin) 10 mg tablets, a significant development announced jointly by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY). This approval pertains to the use of Jardiance in reducing the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, […]
Gilead Sciences said that the US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury (remdesivir) usage in COVID-19 patients with severe renal impairment, encompassing those on dialysis. This approval positions Veklury as the sole antiviral COVID-19 treatment approved for use in all stages of renal disease. It’s estimated […]
ProKidney, a late clinical-stage cellular therapeutics company, has announced plans to acquire a 210,000 square foot facility and approximately 22 acres of land in Greensboro, North Carolina. The move is aimed at meeting the company’s future commercial manufacturing needs for REACT, a renal autologous cell therapy currently in Phase 3 development for treating diabetic chronic […]